Ovbiagele B, Saver J L, Bang H, Chambless L E, Nassief A, Minuk J, Toole J F, Crouse J R
Stroke Center, Department of Neurology, UCLA School of Medicine, Los Angeles, CA, USA.
Neurology. 2006 Apr 25;66(8):1164-70. doi: 10.1212/01.wnl.0000208403.18885.0e.
National cholesterol guidelines have defined high vascular risk individuals as those who could potentially benefit most from statin therapy. The authors aimed to determine the rate of statin use, its predictors, and the achievement of national guideline target lipid goals among ischemic stroke survivors.
The authors abstracted data from the Vitamin Intervention for Stroke Prevention (VISP) study database from the United States and Canada to incorporate into algorithms for initiating statin therapy according to the National Cholesterol Education Program (NCEP) guidelines for high-risk individuals. The authors applied these algorithms to all study subjects. Univariate as well as multivariate associations for target lipid levels and statin implementation were then evaluated utilizing pertinent demographic, clinical, and laboratory data.
Of 2,894 subjects in the analysis dataset, 38% were women; 71% were recruited in the United States and 29% in Canada. Of 769 high-risk subjects, 262 (34%) had a low-density lipoprotein (LDL) level > or =130 mg/dL and 124 of these (47%) were not on statin. Among those high-risk persons on statin treatment, only 42% had an LDL < or =100 mg/dL. Subjects in the overall cohort were more likely to be on a statin if they were treated in the United States or had a history of hypertension or coronary artery disease.
Approximately one out of three guideline-eligible high vascular risk ischemic stroke patients in this study had low-density lipoprotein cholesterol concentrations above qualifying levels for pharmacologic therapy, but half of these patients were not taking a statin, and of those receiving statin treatment, less than half were within recommended lipid goals.
国家胆固醇治疗指南将高血管风险个体定义为那些可能从他汀类药物治疗中获益最大的人群。作者旨在确定缺血性卒中幸存者中他汀类药物的使用比例、其预测因素以及国家指南目标血脂水平的达成情况。
作者从美国和加拿大的卒中预防维生素干预(VISP)研究数据库中提取数据,以纳入根据国家胆固醇教育计划(NCEP)高危个体指南启动他汀类药物治疗的算法。作者将这些算法应用于所有研究对象。然后利用相关的人口统计学、临床和实验室数据评估目标血脂水平与他汀类药物使用的单变量及多变量关联。
在分析数据集中的2894名受试者中,38%为女性;71%在美国招募,29%在加拿大招募。在769名高危受试者中,262名(34%)的低密度脂蛋白(LDL)水平≥130mg/dL,其中124名(47%)未服用他汀类药物。在接受他汀类药物治疗的高危人群中,只有42%的LDL≤100mg/dL。总体队列中的受试者如果在美国接受治疗或有高血压或冠状动脉疾病史,则更有可能服用他汀类药物。
在本研究中,约三分之一符合指南标准的高血管风险缺血性卒中患者的低密度脂蛋白胆固醇浓度高于药物治疗的合格水平,但这些患者中有一半未服用他汀类药物,而在接受他汀类药物治疗的患者中,不到一半的患者血脂水平达到推荐目标。